European journal of ophthalmology · 2012
Choroidal neovascularization of optic disk melanocytoma treated with bevacizumab.
Клинический случайСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kamisasanuk Taro, Uchino Eisuke, Sakamoto Taiji
Аннотация
PURPOSE: To report a case of choroidal neovascularization (CNV) associated with optic disk melanocytoma successfully treated with bevacizumab.
METHODS: A 63-year-old man complained of visual impairment in his left eye. His visual acuity was 0.9 OS. Fundus examination showed optic disk melanocytoma associated with serous retinal detachment and mild hemorrhage. Fluorescein and indocyanine green angiography revealed CNV adjacent to the optic disc. Intravitreous bevacizumab (IVB) was performed 3 times.
RESULTS: Choroidal neovascularization and serous retinal detachment disappeared at 5 months after IVB. Visual acuity recovered to 1.5 OS and has been stable for 1 year follow-up. No adverse events were found related to IVB.
CONCLUSIONS: Intravitreous bevacizumab can be a beneficial treatment for CNV associated with optic disc melanocytoma.
METHODS: A 63-year-old man complained of visual impairment in his left eye. His visual acuity was 0.9 OS. Fundus examination showed optic disk melanocytoma associated with serous retinal detachment and mild hemorrhage. Fluorescein and indocyanine green angiography revealed CNV adjacent to the optic disc. Intravitreous bevacizumab (IVB) was performed 3 times.
RESULTS: Choroidal neovascularization and serous retinal detachment disappeared at 5 months after IVB. Visual acuity recovered to 1.5 OS and has been stable for 1 year follow-up. No adverse events were found related to IVB.
CONCLUSIONS: Intravitreous bevacizumab can be a beneficial treatment for CNV associated with optic disc melanocytoma.
Предметные рубрики MeSH
Angiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabChoroidal NeovascularizationColoring AgentsFluorescein AngiographyHumansIndocyanine GreenIntravitreal InjectionsMaleMiddle AgedNevus, PigmentedOptic DiskOptic Nerve NeoplasmsTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityVisual Fields